{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:41:31Z","timestamp":1790444491274,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,5,3]],"date-time":"2015-05-03T00:00:00Z","timestamp":1430611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:p>In patients with thalassemia intermedia (TI), such as beta\u2010TI, alpha\u2010thalassemia (mainly HbH disease and mild\/moderate forms of HbE\/beta\u2010thalassemia), iron overload is an important challenge in terms of diagnosis, monitoring, and treatment. Moreover, to date, the only possible chelators available are deferoxamine, deferasirox, and deferiprone. Here, we report the first 5\u2010year long\u2010term randomized clinical trial comparing the effectiveness of deferiprone versus deferoxamine in patients with TI. Body iron burden, which was determined by measuring serum ferritin levels in the same patient over 5 years and analyzed according to the generalized linear mixed model (GLMM), showed a linear decrease over time in the mean serum ferritin levels in both treatment groups (<jats:italic>P<\/jats:italic>\u2010value\u2009=\u20090.035). The overall period of observation was 235.2 person\u2010years for the deferiprone patients compared with 214.3 person\u2010years for the deferoxamine patients. The results of the log\u2010rank test suggested that the deferiprone treatment did not affect survival compared with the deferoxamine treatment (<jats:italic>P<\/jats:italic>\u2010value\u2009=\u20090.360). The major adverse events observed included gastrointestinal symptoms and joint pain or arthralgia. Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control. In conclusion, long\u2010term iron chelation therapy with deferiprone is associated with an efficacy and safety similar to that of deferoxamine, suggesting that this drug is an alternative option in cases in which deferoxamine and deferasirox are contraindicated. Am. J. Hematol. 90:634\u2013638, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24024","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T21:47:51Z","timestamp":1427233671000},"page":"634-638","source":"Crossref","is-referenced-by-count":43,"title":["Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5\u2010year long\u2010term <scp>I<\/scp>talian multicenter randomized clinical trial"],"prefix":"10.1002","volume":"90","author":[{"given":"Giuseppina","family":"Calvaruso","sequence":"first","affiliation":[{"name":"A.O.R. \u201cVilla Sofia \u2013 V Cervello\u2019\u2019 Unit\u00e0 Operativa Complessa Ematologia II Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vitrano","sequence":"additional","affiliation":[{"name":"A.O.R. \u201cVilla Sofia \u2013 V Cervello\u2019\u2019 Unit\u00e0 Operativa Complessa Ematologia II Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Di Maggio","sequence":"additional","affiliation":[{"name":"A.O.R. \u201cVilla Sofia \u2013 V Cervello\u2019\u2019 Unit\u00e0 Operativa Complessa Ematologia II Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Lai","sequence":"additional","affiliation":[{"name":"Dipartimento Di Scienze Mediche Sezione Talassemici Adulti, University of Cagliari  Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Colletta","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Univiversit\u00e0 Policlinico \u201cVittorio Emanuele \u2010P.O Ferrarotto\u201d Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Quota","sequence":"additional","affiliation":[{"name":"A.O. \u2018\u2018V Emanuele III\u2019\u2019 Centro Microcitemia Gela (CL) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogera","family":"Gerardi","sequence":"additional","affiliation":[{"name":"A.O.O.C.R. U.O.S. Di Talassemia Sciacca Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Concetta","family":"Rigoli","sequence":"additional","affiliation":[{"name":"U.O Genetica Ed Immunologia Pediatrica Policlinico \u201cG. Martino\u201d Messina Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Sacco","sequence":"additional","affiliation":[{"name":"A.O.R. \u201cVilla Sofia \u2013 V Cervello\u2019\u2019 Unit\u00e0 Operativa Complessa Ematologia II Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Pitrolo","sequence":"additional","affiliation":[{"name":"A.O.R. \u201cVilla Sofia \u2013 V Cervello\u2019\u2019 Unit\u00e0 Operativa Complessa Ematologia II Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Maggio","sequence":"additional","affiliation":[{"name":"A.O.R. \u201cVilla Sofia \u2013 V Cervello\u2019\u2019 Unit\u00e0 Operativa Complessa Ematologia II Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907083410207"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.047852"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","unstructured":"ViprakasitV Lee\u2010LeeC ChongQT et al.Iron chelation therapy in the management of thalassemia: The Asian perspectives.Int J Hematol2009;90:435\u2013445.","DOI":"10.1007\/s12185-009-0432-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20102"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","unstructured":"TaherAT PorterJB ViprakasitV et al.Deferasirox reduces iron overload significantly in nontransfusion\u2010dependent thalassemia: 1\u2010Year results from a prospective randomized double\u2010blind placebo\u2010controlled study.Blood2012;120:970\u2013977","DOI":"10.1182\/blood-2012-02-412692"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1808-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","unstructured":"MaggioA D'AmicoG MorabitoA.Independent clinical trials.Lancet2004;363:1080.","DOI":"10.1016\/S0140-6736(04)15863-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","unstructured":"MaggioA1 GiambonaA CaiSP et al.Rapid and simultaneous typing of hemoglobin S hemoglobin C and seven Mediterranean beta\u2010thalassemia mutations by covalent reverse dot\u2010blot analysis: Application to prenatal diagnosis in Sicily.Blood1993;81:239\u2013242.","DOI":"10.1182\/blood.V81.1.239.bloodjournal811239"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532393"},{"key":"e_1_2_8_11_1","volume-title":"Extending the linear model with R: Generalized linear, mixed effects and nonparametric regression models","author":"Faraway Julian J.","year":"2006"},{"key":"e_1_2_8_12_1","volume-title":"Modelling survival data in medical research","author":"Collett David.","year":"2003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","unstructured":"AkrawinthawongK ChaowalitN ChatuparisuthT et al.Effectiveness of deferiprone in transfusion\u2010independent beta\u2010thalassemia\/HbE patients.Hematology2011;16:113\u2013122.","DOI":"10.1179\/102453311X12940641877768"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","unstructured":"PootrakulP1 SirankaprachaP SankoteJ et al.Clinical trial of deferiprone iron chelation therapy in beta\u2010thalassaemia\/haemoglobin E patients in Thailand.Br J Haematol2003;122:305\u2010310.","DOI":"10.1046\/j.1365-2141.2003.04412.x"},{"key":"e_1_2_8_15_1","unstructured":"RombosY TzaneteaR KonstantopoulosK et al.Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).Haematologica2000;85:115\u2013117."},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V79.10.2741.bloodjournal79102741","article-title":"Reduction of tissue iron stores and normalizationof serum ferritin during treatment with the oral iron chelator l1 in thalassemia intermedia","volume":"79","author":"Olivieri NF","year":"1992","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","unstructured":"ChanJC ChimCS OoiCG et al.Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease.Br J Haematol2006;133:198\u2013205.","DOI":"10.1111\/j.1365-2141.2006.05984.x"},{"key":"e_1_2_8_18_1","article-title":"Serum ferritin level and morbidity risk in transfusion\u2010independent patients with \u03b2\u2010thalassemia intermedia: The ORIENT study","author":"Musallam KM","journal-title":"Haematologica"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21215"},{"key":"e_1_2_8_20_1","first-page":"0927","article-title":"Estimation of liver iron concentration by serum ferritin measurement in non\u2010transfusion\u2010depedent thalassemia patients: Analysis from the 1\u2010year THALASSA study (abstract)","volume":"96","author":"Taher A","year":"2012","journal-title":"Haematologica"},{"key":"e_1_2_8_21_1","unstructured":"TaherA PorterJ ViprakasitV et al.Serum ferritin for predicting clinically relevant LIC thresholds to guide management of patients with non\u2010transfusion\u2010depedent\u2010thalassemia treated with deferasirox: THALASSA study extension analysis (Abstract).Haematologica2013;98:486."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24024","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:00:24Z","timestamp":1695542424000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,3]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/ajh.24024"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24024","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,3]]}}}